Bausch + Lomb Corporation (BLCO)Healthcare | Medical Instruments & Supplies | Vaughan, Canada | NYSE
17.15 USD
+0.02
(0.117%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 17.15 |
Hot Take ↕ | Aug. 22, 2026, 3:01 a.m. EDT
The investment case here is severely compromised by a complete lack of shareholder returns and deteriorating operational performance. The company has suspended its glaucoma eye drop program following a trial failure, a significant setback in its therapeutic portfolio, while simultaneously posting negative earnings and negative returns on equity. With no dividends paid over the last five years, the stock offers zero income, forcing investors to rely entirely on capital appreciation in a business that has failed to generate consistent growth over the past three years. While the forward P/E looks attractive at 15.8x, this is a classic value trap where the low price reflects the reality of a struggling business rather than a margin of safety. The recent price action shows some stabilization near the 17.00 level, but the fundamental damage—negative profitability, halted drug development, and a flat-to-downward multi-year trajectory—makes this a difficult hold for long-term capital preservation. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.043164 |
| AutoETS | 0.043234 |
| AutoTheta | 0.043271 |
| MSTL | 0.043674 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 1.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.209 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 79.376 |
| Revenue per Share | 14.987 |
| Market Cap | 6,125,383,680 |
| Forward P/E | 15.69 |
| Beta | 0.55 |
| Profit Margins | -3.21% |
| Website | https://www.bausch.com |
As of Aug. 22, 2026, 3:01 a.m. EDT: Speculators are positioning for a range-bound or slightly lower scenario. Call volume is heavily skewed toward out-of-the-money strikes (19.0 and 20.0), suggesting a speculative hope for a rebound to the upper end of the trading range, while put volume concentrates at the 15.0 and 16.0 strikes, indicating a floor defense strategy. The lack of significant long-dated call interest beyond February 2027 suggests skepticism regarding a major structural breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.1566509 |
| Address1 | 520 Applewood Crescent |
| All Time High | 21.95 |
| All Time Low | 10.45 |
| Ask | 17.18 |
| Ask Size | 200 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.4 - Buy |
| Average Daily Volume10 Day | 394,050 |
| Average Daily Volume3 Month | 422,608 |
| Average Volume | 422,608 |
| Average Volume10Days | 394,050 |
| Beta | 0.554 |
| Bid | 17.16 |
| Bid Size | 600 |
| Board Risk | 5 |
| Book Value | 18.093 |
| City | Vaughan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.15 |
| Current Ratio | 1.546 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 17.3 |
| Day Low | 16.945 |
| Debt To Equity | 79.376 |
| Display Name | Bausch + Lomb |
| Earnings Call Timestamp End | 1,785,326,400 |
| Earnings Call Timestamp Start | 1,785,326,400 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,793,190,600 |
| Earnings Timestamp Start | 1,793,190,600 |
| Ebitda | 816,000,000 |
| Ebitda Margins | 0.15326999 |
| Enterprise To Ebitda | 13.409 |
| Enterprise To Revenue | 2.055 |
| Enterprise Value | 10,941,383,680 |
| Eps Current Year | 0.80393 |
| Eps Forward | 1.09336 |
| Eps Trailing Twelve Months | -0.48 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.5132 |
| Fifty Day Average Change | 0.63679886 |
| Fifty Day Average Change Percent | 0.038563017 |
| Fifty Two Week Change Percent | 15.665091 |
| Fifty Two Week High | 18.915 |
| Fifty Two Week High Change | -1.7650013 |
| Fifty Two Week High Change Percent | -0.09331225 |
| Fifty Two Week Low | 13.765 |
| Fifty Two Week Low Change | 3.3849993 |
| Fifty Two Week Low Change Percent | 0.24591349 |
| Fifty Two Week Range | 13.765 - 18.915 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,651,843,800,000 |
| Float Shares | 45,502,852 |
| Forward Eps | 1.09336 |
| Forward P E | 15.685594 |
| Free Cashflow | 323,000,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 13,000 |
| Fullday Change | 0.0200005 |
| Fullday Change Percent | 0.116757 |
| Fullday Price | 17.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.61439 |
| Gross Profits | 3,271,000,064 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.87342 |
| Held Percent Institutions | 0.11143 |
| Implied Shares Outstanding | 357,165,246 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. |
| Long Name | Bausch + Lomb Corporation |
| Market | us_market |
| Market Cap | 6,125,383,680 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1678122959 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -171,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,077,005,394 |
| Number Of Analyst Opinions | 12 |
| Open | 17.16 |
| Operating Cashflow | 458,000,000 |
| Operating Margins | 0.077470005 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.89 |
| Phone | 905 695 7700 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 17.15 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 17.13 |
| Price Eps Current Year | 21.332703 |
| Price Hint | 2 |
| Price To Book | 0.9478803 |
| Price To Sales Trailing12 Months | 1.1505228 |
| Profit Margins | -0.03212 |
| Quick Ratio | 0.812 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.38462 |
| Region | US |
| Regular Market Change | 0.0200005 |
| Regular Market Change Percent | 0.116757 |
| Regular Market Day High | 17.3 |
| Regular Market Day Low | 16.945 |
| Regular Market Day Range | 16.945 - 17.3 |
| Regular Market Open | 17.16 |
| Regular Market Previous Close | 17.13 |
| Regular Market Price | 17.15 |
| Regular Market Time | 1,787,947,202 |
| Regular Market Volume | 403,112 |
| Return On Assets | 0.01828 |
| Return On Equity | -0.02517 |
| Revenue Growth | 0.091 |
| Revenue Per Share | 14.987 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 357,165,246 |
| Shares Percent Shares Out | 0.0089 |
| Shares Short | 3,180,547 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,800,176 |
| Short Name | Bausch + Lomb Corporation |
| Short Percent Of Float | 0.069699995 |
| Short Ratio | 7.54 |
| Source Interval | 15 |
| State | ON |
| Symbol | BLCO |
| Target High Price | 23.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 18.625 |
| Target Median Price | 18.25 |
| Total Cash | 367,000,000 |
| Total Cash Per Share | 1.028 |
| Total Debt | 5,114,999,808 |
| Total Revenue | 5,324,000,256 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.4942 |
| Two Hundred Day Average Change | 0.65579987 |
| Two Hundred Day Average Change Percent | 0.039759424 |
| Type Disp | Equity |
| Volume | 403,112 |
| Website | https://www.bausch.com |
| Zip | L4K 4B4 |